Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Rhumbline Advisers

Rhumbline Advisers lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,928 shares of the company's stock after buying an additional 5,771 shares during the quarter. Rhumbline Advisers owned approximately 0.11% of Kymera Therapeutics worth $1,914,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KYMR. State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at approximately $55,000. Tower Research Capital LLC TRC raised its position in shares of Kymera Therapeutics by 95.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock valued at $194,000 after purchasing an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after acquiring an additional 406 shares during the last quarter. Finally, Vident Advisory LLC bought a new stake in shares of Kymera Therapeutics in the 4th quarter valued at approximately $236,000.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $46.35 on Wednesday. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The business has a 50-day moving average of $33.68 and a two-hundred day moving average of $35.78. The company has a market capitalization of $3.02 billion, a P/E ratio of -14.95 and a beta of 2.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company's revenue for the quarter was up 114.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.69) earnings per share. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on KYMR. UBS Group lowered their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. Morgan Stanley raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $49.00 to $79.00 in a research note on Tuesday, June 3rd. Finally, Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $59.82.

Insider Transactions at Kymera Therapeutics

In related news, Director Elena Ridloff sold 12,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Insiders sold 48,349 shares of company stock valued at $2,334,301 over the last three months. Company insiders own 16.01% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.